Neuraxis, Inc. NRXS 深 滬
等待開盤 12-24 09:30:00 美东时间
3.54
-0.490
-12.16%
華盛通- 最 高4.24
- 今 開3.955
- 成交量 31.64万股
- 最 低 3.41
- 昨 收 4.03
- 總市值 3494.97万
- 52周最高 6.20
- 市盈率 靜 --
- 換手率 3.20%
- 52周最低 1.33
- 委 比 0.00%
- 總股本 987.28万
- 歷史最高 6.93
- 量 比 0.10
- 振 幅 20.60%
- 歷史最低 1.33
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
12-23 12:32
Craig-Hallum Maintains Buy on Neuraxis, Raises Price Target to $8
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the price target from $7 to $8.
12-23 00:26
NeurAxis Rolls Out New Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation
NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced
12-19 21:02
Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 4 percent increase over losses of $(0.25) per share from the same
11-11 06:53
Neuraxis Earnings Preview
Neuraxis (AMEX:NRXS) is gearing up to announce its quarterly earnings on Tuesda...
11-11 00:03
NeurAxis Expands Stock Offering to $6.27 Million
NeurAxis, Inc. ( ($NRXS) ) has issued an announcement. NeurAxis, Inc. has recei...
10-24 20:48
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis has received FDA clearance for its PENFS technology to treat functional abdominal pain and nausea in patients aged 8 and older, marking the first FDA-approved treatment for adults with functional dyspepsia. This expansion includes a new CPT code effective January 1, 2026, enhancing its market reach and offering a non-invasive solution for patients with limited treatment options.
10-24 12:00
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Nurix Therapeutics announced clinical data from the Phase 1a study of NX-1607, a first-in-class oral CBL-B inhibitor for treating advanced solid tumors. NX-1607 showed on-target immune activation and anti-tumor activity, including tumor biomarker reductions, tumor shrinkage, and partial responses in heavily pretreated patients. Results from 82 patients across 11 tumor types demonstrated dose-dependent activity, with a 49.3% disease control rate. ...
10-18 07:00
NeurAxis Enters Market Offering Agreement with Craig-Hallum
NeurAxis, Inc. ( ($NRXS) ) has provided an update. On August 29, 2025, Neuraxis...
09-02 21:52
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 47.62 percent increase over losses of $(0.42) per share from the same
08-12 19:05
